Elisa Gozzi's research while affiliated with Regina Apostolorum Hospital and other places

... The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein belonging to the epidermal growth factor (EGF) family [8], and increased EGFR expression has been linked to a poor prognosis and outcome for a variety of cancers [9]. Systemic anti-EGFR medicines, such as cetuximab (CXT) and nimotuzumab (NTZ), have shown modest efficacy in clinical trials for nasopharyngeal cancer [10], but the results have been inconsistent [11][12][13]. It is also unknown whether combining anti-EGFR medicines with standard therapy increases the risk of bad outcomes. ...

... Furthermore, despite having similar benefits in OS and PFS, men over 75 years old with mCSPC in the ARCHES study also experience more dose interruptions and reductions than <75-year-olds (32.1% versus 18.1%).17 The efficacy of this practice in octogenarians has been reported in several case reports[79][80][81] and real-world data suggest mCRPC patients who are older, with poor ECOG status and more cardiovascular issues, are more likely to get dose reductions of enzalutamide to 80 mg from the standard 160 mg and still, have comparable disease control and progression-free survival.82 A follow-up retrospective by the same authors revealed that starting with a ⩽50% dose of enzalutamide (⩽80 mg/ day) versus standard dose (160 mg/day) may also improve longevity (measured by restrict-mean survival time) while lowering AEs and not compromising efficacy; this effect was seen regardless of age.83 ...

... Prognosis is poor because it is usually indicative of disseminated disease. It is important to distinguish breast metastasis from primary breast carcinoma in order to plan the most suitable treatment [8]. Treatment experience is uncomfortable due to the rarity of the metastatic pattern. ...

... Intraocular metastasis occurs in 2-9% of all malignancies, mostly arising from breast cancer (53%), and lung cancer (20%). 1 The choroid has a vascular system that supplies rich blood for circulating tumor cells (CTC) or tumor emboli to grow, making it the most common site of intraocular metastasis. 2 Clinical manifestations of CM vary from blurred vision (70-81%), flashes and floaters (5-12%), and pain (5-14%), to no symptoms (9-11%). 3 The treatment of CM, either systemic or primary, depends on the status, number and location lesion. Current treatments include chemotherapy, radiotherapy, targeted therapy and immunotherapy. ...

... Breast cancer occurs bilaterally in about 3% of all breast cancers, with synchronous tumors accounting for 0.6% and metachronous tumors accounting for 2.2% [3] . SBBC are rare, with limited treatment options available for the patients [4] . Pathologically different bilateral breast cancers account for only 1%-2% of cases [5] . ...

... 12 While the patient in case 3 had this tattoo for many years, her eruption appeared 2 months after nivolumab initiation and resolved upon drug discontinuation, supporting that this was likely a pseudolymphomatous tattoo reaction to nivolumab. Post-herpetic granulomatous dermatitis has been reported both weeks and months after initiation of nivolumab which is in accordance with the time course noted in case 4. 13,14 The extragenital lichen sclerosus in case 5 has also been reported in a patient with uveal melanoma on nivolumab who was also noted to have previously experienced melanoma-associated leukoderma related to nivolumab. 15 ...